Exco InTouch Achieve a New First in Mobile Clinical Technology
Exco InTouch, the leading provider of digital patient engagement and data capture solutions for clinical research and healthcare providers has announced a new first in the clinical technology arena. Having pioneered the use of mobile technology, increasing retention and compliance through engaging and supporting patients, and facilitating the delivery of ePRO via mobile devices, the forward looking company are now the only electronic Clinical Outcomes Assessment (eCOA) provider to have published public-facing apps on all three mobile operating platforms (iOS, Android and Windows8).
Dale Jessop, CTO at Exco InTouch, commented: “We’re thrilled to have reached this milestone, and even more so having used native apps, as this provides the user with device specific natural controls — driving familiarity and ease of use. Currently the most common approach is to use HTML5, which wraps a web app into mobile operating controls, however, this does not enable the layout to be optimised for the device in use, or incorporate natural button configurations and so does not present the best experience for patients. In contrast, our pedigree in developing mobile solutions for clinical and healthcare programs has enabled us to deliver the benefits of native apps in a timely, cost effective manner across all platforms.”
The variety of apps developed for clients by Exco InTouch covers a broad range of therapeutic areas, from cardiovascular and respiratory diseases through to smoking cessation and vaccination programmes, utilising their flexible platform which adapts to individual programme needs. The platform enables the integration of medical device data and also lifestyle devices, such as FitBit, which are increasingly popular in clinical research to provide secondary outcomes data.
The company’s leading approach enables its clients to select their preferred delivery model, offering the flexibility to either provision appropriate devices for the study population, or more significantly to enable BYOD (Bring Your Own Device) in both clinical and commercial programs. This is enabled by proprietary mDNA technology, which provides sponsors and payers the robust reassurance of protecting Personally Identifiable Information (PII) and maintaining data security even when using the patients’ own devices.
Tim Davis, CEO and founder of Exco InTouch, commented: “We are leading the way in delivering native apps across all three mobile operating platforms, which not only is an achievement for our company, but also another great milestone for the entire clinical industry. There is huge demand in the industry for eCOA providers to deliver user friendly solutions that the patient finds easy to use and accessible. A clinical trial is reliant on timely engagement from its patients and we are delighted to be foremost in improving patients’ user experience.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.